Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
Open Access
- 1 April 1999
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (4) , 445-449
- https://doi.org/10.1046/j.1365-2125.1999.00898.x
Abstract
Aims The cytochrome P450 enzyme CYP1A2 metabolises several drugs and carcinogens. We wanted to determine how much of the variability of CYP1A2 activity is explained by a newly discovered gene polymorphism in intron 1.Methods A single nucleotide polymorphism in intron 1 of the CYP1A2 gene at position 734 downstream of the first transcribed nucleotide was identified by DNA sequence analysis. The functional significance of this C/A polymorphism was assessed in 185 healthy Caucasian non‐smokers and in 51 smokers by genotyping and phenotyping using caffeine (100 mg oral dose).Results Out of the total sample, 46% were homozygous for the variant A, 44% were heterozygous, and 10% were homozygous for the variant C. The ratio of 1,7‐dimethylxanthine (17X) plus 1,7‐dimethyluric acid divided by caffeine in 0–5 h urine samples from 185 non‐smokers did not differ significantly between the three CYP1A2 genotypes. In the 51 smokers, analysis of variance revealed significant differences in the 5 h plasma 17X/caffeine ratios between the genotypes (P=0.008, F‐test). The mean ratio was 1.37 in carriers of the A/A genotype, 0.88 in heterozygotes and 0.82 in carriers of C/C. The mean difference between the A/A and C/A groups was 0.48 (95% confidence interval 0.15–0.81; P=0.01).Conclusions The A/A genotype, which may represent a CYP1A2 high inducibility genotype, may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. Further studies are needed to define the role of this polymorphism on the pharmacokinetics of drugs metabolised by CYP1A2 and in the activation of carcinogens.Keywords
This publication has 16 references indexed in Scilit:
- Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997
- Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populationsPharmacogenetics, 1995
- Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activityPharmacogenetics, 1995
- A population and family study of CYP1A2 using caffeine urinary metabolitesEuropean Journal of Clinical Pharmacology, 1995
- Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.1994
- Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in salivaPharmacogenetics, 1994
- Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoinClinical Pharmacology & Therapeutics, 1992
- Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolitesPharmacogenetics, 1992
- Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activitiesClinical Pharmacology & Therapeutics, 1991
- A simple test for acetylator phenotype using caffeine.British Journal of Clinical Pharmacology, 1984